Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $0.47, for a total value of $31,936.50. Following the transaction, the director directly owned 763,685 shares in the company, valued at approximately $358,931.95. This trade represents a 8.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $39,341.25.
- On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total value of $15,282.54.
- On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total value of $36,934.85.
- On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $28,336.50.
- On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total value of $11,092.00.
- On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $43,446.40.
- On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total value of $22,745.16.
- On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total value of $214,018.70.
- On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $49,824.18.
- On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total value of $9,659.10.
Werewolf Therapeutics Stock Up 4.4%
HOWL stock traded up $0.02 on Tuesday, reaching $0.46. 797,900 shares of the company’s stock were exchanged, compared to its average volume of 465,332. The stock has a fifty day moving average of $0.77 and a 200-day moving average of $0.77. Werewolf Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $2.38. The firm has a market cap of $22.51 million, a PE ratio of -0.37 and a beta of 0.41.
Institutional Trading of Werewolf Therapeutics
Institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the first quarter valued at $79,000. Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at $113,000. Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at $48,000. Jane Street Group LLC purchased a new stake in shares of Werewolf Therapeutics in the second quarter valued at $409,000. Finally, Bank of America Corp DE lifted its position in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after acquiring an additional 25,882 shares in the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of analysts have commented on HOWL shares. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.75.
Read Our Latest Stock Report on Werewolf Therapeutics
Werewolf Therapeutics Company Profile
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Articles
- Five stocks we like better than Werewolf Therapeutics
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
